vTv Therapeutics (NASDAQ:VTVT) Announces Earnings Results, Misses Estimates By $0.11 EPS

vTv Therapeutics (NASDAQ:VTVT) released its earnings results on Thursday. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.11), FiscalAI reports.

vTv Therapeutics Stock Up 2.2%

vTv Therapeutics stock traded up $0.55 during mid-day trading on Friday, hitting $26.02. The company’s stock had a trading volume of 17,606 shares, compared to its average volume of 10,990. The stock has a market capitalization of $102.47 million, a P/E ratio of -8.34 and a beta of 0.66. vTv Therapeutics has a twelve month low of $12.62 and a twelve month high of $27.00. The stock’s fifty day moving average price is $21.61 and its two-hundred day moving average price is $18.63.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on VTVT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of vTv Therapeutics in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of vTv Therapeutics in a research report on Wednesday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, vTv Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $35.50.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.